Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,835 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Volunteers Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

NCT02869893
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Secretin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 24, 2026, 11:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

NCT00648414
View directory record Official record
Conditions
Healthy
Interventions
Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 24, 2026, 11:37 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

NCT07829406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NNC0642-1895, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Food Intake Response to Short-Term Modifications of Metabolism in Humans

NCT02939404
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cold exposure, Normal temperature, Fixed diet, Ad libitum diet, Fasting
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 24, 2026, 11:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Biological Effects of Ultrasound Insonification of the Spleen

NCT03548116
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ultrasound, Sham Ultrasound
Device
Lead sponsor
John Pellerito
Other
Eligibility
18 Years to 45 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of Golden Rice Carotenoids in Humans

NCT00680355
View directory record Official record
Conditions
Healthy
Interventions
golden rice, corn oil 0g, corn oil 10g, coren oil 5 g
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

NCT04056468
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers

NCT01508832
View directory record Official record
Conditions
Onset and Duration of a Digital Nerve Block
Interventions
Lidocaine Digital Nerve Block, Bupivacaine Digital Block
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

NCT00046358
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lovostatin, Ibuprofen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

NCT01420458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Experimental
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

NCT03838185
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
J147, Placebo
Drug
Lead sponsor
Abrexa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 24, 2026, 11:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

NCT05418868
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir 200 mg/mL, Cabotegravir >=400 mg/mL, Cabotegravir Formulation I, CAB Formulation J, rHuPH20, RPV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orlando, Florida • Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

NCT02096744
View directory record Official record
Conditions
Healthy
Interventions
Catapres-TTS-1, Intervention 1: Catapres-TTS-3, Intervention 2: Catapres-TTS-3
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage

NCT02934321
View directory record Official record
Conditions
Satiety in Healthy Volunteers
Interventions
Erythritol, Aspartame
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

NCT01072214
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics

NCT01822665
View directory record Official record
Conditions
Gastrointestinal Mucosal Damage
Interventions
Ibuprofen, Paracetamol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Simvastatin and Albiglutide

NCT01147692
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simvastatin plus albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

NCT04484532
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

INDV-2000 First in Human

NCT04413552
View directory record Official record
Conditions
Opioid Dependence
Interventions
INDV-2000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 24, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

NCT03542435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SXC-2023, Placebo
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 24, 2026, 11:37 PM EDT